Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Ap...(lzheimer's pathology is thepresence of i...),Health

Date:10/8/2008

lzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are more than 5 million Americans and about 30 million people suffering from Alzheimer's disease world wide with the number expected to increase dramatically as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate more than $6 billion in sales by 2010, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The company has a broad proprietary immunotherapy platform for both passive and active immunization against Alzheimer's disease. Also, Intellect has completed Phase I clinical trials for OXIGON(TM), which has potential to treat Alzheimer's disease and other serious disorders.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-look
'/>"/>

SOURCE Intellect Neurosciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Depression can foreshadow intellectual decline in older people
2. Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor
3. Written Statement of Kevin J. OConnor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement
4. StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform
5. Allarae Healthcare Inc. Announces Signing of Distribution Agreement With Intellect Inc.
6. John Josef Molenda Joins Firms Intellectual Property Practice as Of Counsel
7. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
8. CJPS Enterprises Spins Off New Company for Intellectual Property Marketing
9. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
10. Mutant gene causes epilepsy, intellectual disability in women
11. Intellectual Property Buildup Seminar to be Held in Detroit